Impact BioMedical
20 hedge funds and large institutions have $2.23M invested in Impact BioMedical in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 7 closing their positions.
1,476% more capital inflows, than outflows
Capital inflows: $1.65M | Capital outflows: $105K
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
18.73% more ownership
Funds ownership: 11.82% → 30.55% (+19%)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
5% less funds holding
Funds holding: 21 → 20 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$559K |
| 2 |
State Street
Boston,
Massachusetts
|
+$298K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$117K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.1K |
| 5 |
Global Trust Asset Management
West Palm Beach,
Florida
|
+$908 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$69.6K |
| 2 |
Two Sigma Securities
New York
|
-$11.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.33K |
| 4 |
Jane Street
New York
|
-$7.11K |
| 5 |
HRT Financial
New York
|
-$6K |
IBO Hedge Fund Activity: Q1 2026 in Review
20 of the 8,240 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q1 2026, worth a combined $2.23M — up 208% from $726K a quarter earlier.
Fund positioning in IBO was balanced in Q1 2026: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $559K. The largest seller was Millennium Management, exiting entirely with an estimated $69.6K sold.
- 20 institutional investors held Impact BioMedical (IBO) as of Q1 2026, down from 21 in Q4 2025.
- Funds reported $2.23M of Impact BioMedical stock for Q1 2026, up 208% quarter-over-quarter.
- 7 funds opened new Impact BioMedical positions in Q1 2026 and 7 closed out, a net change of 0 holders.
- The largest Impact BioMedical buyer in Q1 2026 was Geode Capital Management, an estimated $559K added.
- The largest Impact BioMedical seller in Q1 2026 was Millennium Management, an estimated $69.6K sold.
Based on aggregated 13F filings for Q1 2026.